Modest slowdown in premium growth distinguishes second-quarter financial results for MPL specialty insurers
We look at the financial results for medical professional liability (MPL) insurers for the second quarter of 2022.
On January 31, 2019, the U.S. Department of Health and Human Services Office of the Inspector General proposed a rule that would eliminate the long-standing safe harbor protection for prescription drug manufacturer rebates paid to Medicare Part D sponsors and pharmacy benefit managers. Under the proposed rule, manufacturer rebates paid to Part D plans would be protected by a new safe harbor only if the amount of the rebate was set in advance and used to reduce the price at the point of sale. The proposed rule would shift the risk dynamics among the beneficiaries, government, and manufacturers and affect how Part D plan sponsors make money, compete, and manage risk. This paper describes how the proposed rule may affect the Part D market.
This article was commissioned by PhRMA.
A world without rebates? How will the Part D market react to the new proposed safe harbor for rebates?
This paper describes how the proposed rule to eliminate the long-standing safe harbor protection for prescription drug rebates paid to Medicare Part D sponsors and pharmacy benefit managers may affect the Medicare Part D market.